{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T23:37:40Z","timestamp":1793230660414,"version":"4.5.0"},"reference-count":233,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82341201"],"award-info":[{"award-number":["82341201"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82170212"],"award-info":[{"award-number":["82170212"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key R&D Program of China","doi-asserted-by":"crossref","award":["2023YFC2508905"],"award-info":[{"award-number":["2023YFC2508905"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Chongqing Medical Scientific Research project","award":["2025CCXM002"],"award-info":[{"award-number":["2025CCXM002"]}]},{"name":"Special Project for Talent Construction in Xinqiao Hospital of Army Medical University","award":["2022XKRC001"],"award-info":[{"award-number":["2022XKRC001"]}]},{"name":"Chongqing Science and Health Collaborative Major Project on Medical Science and Technology Innovation","award":["2024DBXM004"],"award-info":[{"award-number":["2024DBXM004"]}]},{"name":"Clinical Research Special Project of the Second Affiliated Hospital, Army Medical University","award":["2024F010"],"award-info":[{"award-number":["2024F010"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"DOI":"10.1186\/s13045-025-01746-7","type":"journal-article","created":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:43:28Z","timestamp":1761565408000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Recent advances in CAR-MSCs: the new engine of cellular immunotherapy evolution"],"prefix":"10.1186","volume":"18","author":[{"given":"Ying","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingying","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjun","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lun","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,27]]},"reference":[{"issue":"1","key":"1746_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-024-00583-7","volume":"13","author":"P Yao","year":"2024","unstructured":"Yao P, Liu Y-G, Huang G, Hao L, Wang R. The development and application of chimeric antigen receptor natural killer (CAR-NK) cells for cancer therapy: current state, challenges and emerging therapeutic advances. Exp Hematol Oncol. 2024;13(1):118.","journal-title":"Exp Hematol Oncol"},{"issue":"6","key":"1746_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00688-4","volume":"12","author":"C Zhang","year":"2022","unstructured":"Zhang C, He J, Liu L, Wang J, Wang S, Liu L, et al. Novel CD19 chimeric antigen receptor T cells manufactured next-day for acute lymphoblastic leukemia. Blood Cancer J. 2022;12(6):96.","journal-title":"Blood Cancer J"},{"issue":"6","key":"1746_CR3","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1038\/s41375-020-01056-6","volume":"35","author":"C Zhang","year":"2021","unstructured":"Zhang C, Wang X-Q, Zhang R-L, Liu F, Wang Y, Yan Z-L, et al. Donor-derived CD19 CAR-T cell therapy of relapse of CD19-positive B-ALL post allotransplant. Leukemia. 2021;35(6):1563\u201370.","journal-title":"Leukemia"},{"issue":"1","key":"1746_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-024-00679-6","volume":"12","author":"D Zhou","year":"2024","unstructured":"Zhou D, Zhu X, Xiao Y. Advances in CAR-T therapy for central nervous system tumors. Biomark Res. 2024;12(1):132.","journal-title":"Biomark Res"},{"issue":"1","key":"1746_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-024-00634-5","volume":"12","author":"F Nasiri","year":"2024","unstructured":"Nasiri F, Asaadi Y, Mirzadeh F, Abdolahi S, Molaei S, Gavgani SP, et al. Updates on CAR T cell therapy in multiple myeloma. Biomark Res. 2024;12(1):102.","journal-title":"Biomark Res"},{"key":"1746_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-017-0102-y","volume":"5","author":"C Zhang","year":"2017","unstructured":"Zhang C, Liu J, Zhong JF, Zhang X. Engineering CAR-T cells. Biomark Res. 2017;5:22.","journal-title":"Biomark Res"},{"issue":"1","key":"1746_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00910-5","volume":"13","author":"R Huang","year":"2020","unstructured":"Huang R, Li X, He Y, Zhu W, Gao L, Liu Y, et al. Recent advances in CAR-T cell engineering. J Hematol Oncol. 2020;13(1):86.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"1746_CR8","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3892\/ijmm.2015.2413","volume":"37","author":"JS Heo","year":"2016","unstructured":"Heo JS, Choi Y, Kim H-S, Kim HO. Comparison of molecular profiles of human mesenchymal stem cells derived from bone marrow, umbilical cord blood, placenta and adipose tissue. Int J Mol Med. 2016;37(1):115\u201325.","journal-title":"Int J Mol Med"},{"issue":"1","key":"1746_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-024-00532-4","volume":"13","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Wang C, Li JJ. Revisiting the role of mesenchymal stromal cells in cancer initiation, metastasis and immunosuppression. Exp Hematol Oncol. 2024;13(1):64.","journal-title":"Exp Hematol Oncol"},{"issue":"17","key":"1746_CR10","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1200\/JCO-24-02119","volume":"43","author":"H Yao","year":"2025","unstructured":"Yao H, Huang R, Fu H, Lin R, Zhang Y, Feng Y, et al. Sequential infusion of mesenchymal stem cell for Graft-Versus-Host disease prevention in haploidentical hematopoietic stem cell transplantation: an open-label, multicenter, randomized controlled clinical trial. J Clin Oncol. 2025;43(17):1997\u20132006. https:\/\/doi.org\/10.1200\/JCO-24-02119","journal-title":"J Clin Oncol"},{"issue":"3","key":"1746_CR11","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1093\/stcltm\/szad088","volume":"13","author":"J Matas","year":"2024","unstructured":"Matas J, Garc\u00eda C, Poblete D, Vernal R, Ortloff A, Luque-Campos N, et al. A phase I dose-escalation clinical trial to assess the safety and efficacy of umbilical cord-derived mesenchymal stromal cells in knee osteoarthritis. Stem Cells Transl Med. 2024;13(3):193\u2013203.","journal-title":"Stem Cells Transl Med"},{"issue":"Supplement 1","key":"1746_CR12","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1182\/blood-2022-158872","volume":"140","author":"O Sirpilla","year":"2022","unstructured":"Sirpilla O, Sakemura RL, Hefazi M, Girsch JH, Huynh T, Cox MJ, et al. Chimeric antigen receptor engineering of mesenchymal stromal cells (CAR-MSC) enhance immunosuppression and outcomes in graft versus host disease (GvHD) preclinical models. Blood. 2022;140(Supplement 1):1579\u201380.","journal-title":"Blood"},{"issue":"7\u20138","key":"1746_CR13","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/s41417-018-0062-x","volume":"27","author":"G Golinelli","year":"2020","unstructured":"Golinelli G, Grisendi G, Prapa M, Bestagno M, Spano C, Rossignoli F, et al. Targeting GD2-positive glioblastoma by chimeric antigen receptor empowered mesenchymal progenitors. Cancer Gene Ther. 2020;27(7\u20138):558\u201370.","journal-title":"Cancer Gene Ther"},{"issue":"1","key":"1746_CR14","doi-asserted-by":"publisher","first-page":"101240","DOI":"10.1016\/j.tranon.2021.101240","volume":"15","author":"G Golinelli","year":"2022","unstructured":"Golinelli G, Grisendi G, Dall\u2019Ora M, Casari G, Spano C, Talami R, et al. Anti-GD2 CAR MSCs against metastatic ewing\u2019s sarcoma. Transl Oncol. 2022;15(1):101240.","journal-title":"Transl Oncol"},{"issue":"1","key":"1746_CR15","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1186\/s12964-023-01191-4","volume":"21","author":"L Yan","year":"2023","unstructured":"Yan L, Li J, Zhang C. The role of MSCs and CAR-MSCs in cellular immunotherapy. Cell Commun Signal. 2023;21(1):187.","journal-title":"Cell Commun Signal"},{"issue":"8","key":"1746_CR16","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1136\/thorax-2023-220819","volume":"79","author":"TD Shaw","year":"2024","unstructured":"Shaw TD, Krasnodembskaya AD, Schroeder GN, Doherty DF, Silva JD, Tandel SM, et al. Human mesenchymal stromal cells inhibit Mycobacterium avium replication in clinically relevant models of lung infection. Thorax. 2024;79(8):778\u201387.","journal-title":"Thorax"},{"issue":"1","key":"1746_CR17","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1186\/s12967-024-05486-z","volume":"22","author":"L Wang","year":"2024","unstructured":"Wang L, Deng Z, Li Y, Wu Y, Yao R, Cao Y, et al. Ameliorative effects of mesenchymal stromal cells on senescence associated phenotypes in naturally aged rats. J Transl Med. 2024;22(1):722.","journal-title":"J Transl Med"},{"issue":"24","key":"1746_CR18","doi-asserted-by":"publisher","first-page":"10024","DOI":"10.1073\/pnas.86.24.10024","volume":"86","author":"G Gross","year":"1989","unstructured":"Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci U S A. 1989;86(24):10024\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"1746_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-024-01626-6","volume":"17","author":"C Zhang","year":"2024","unstructured":"Zhang C, Wang X, Yi H, Wang Y, Yan Z, Zhou J, et al. Long-term survival with donor CD19 CAR-T cell treatment for relapsed patients after allogeneic hematopietic stem cell transplantation. J Hematol Oncol. 2024;17(1):103.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"1746_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01244-0","volume":"15","author":"J Tan","year":"2022","unstructured":"Tan J, Jia Y, Zhou M, Fu C, Tuhin IJ, Ye J, et al. Chimeric antigen receptors containing the OX40 signalling domain enhance the persistence of T cells even under repeated stimulation with multiple myeloma target cells. J Hematol Oncol. 2022;15(1):39.","journal-title":"J Hematol Oncol"},{"key":"1746_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8722-6-33","volume":"6","author":"C-J Shen","year":"2013","unstructured":"Shen C-J, Yang Y-X, Han EQ, Cao N, Wang Y-F, Wang Y, et al. Chimeric antigen receptor containing ICOS signaling domain mediates specific and efficient antitumor effect of T cells against EGFRvIII expressing glioma. J Hematol Oncol. 2013;6:33.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"1746_CR22","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s13045-018-0635-z","volume":"11","author":"Y Han","year":"2018","unstructured":"Han Y, Xie W, Song D-G, Powell DJ. Control of triple-negative breast cancer using ex vivo self-enriched, costimulated NKG2D CAR T cells. J Hematol Oncol. 2018;11(1):92.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"1746_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-017-0405-3","volume":"10","author":"J Liu","year":"2017","unstructured":"Liu J, Zhong JF, Zhang X, Zhang C. Allogeneic CD19-CAR-T cell infusion after allogeneic hematopoietic stem cell transplantation in B cell malignancies. J Hematol Oncol. 2017;10(1):35.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"1746_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-024-01625-7","volume":"17","author":"K Ai","year":"2024","unstructured":"Ai K, Liu B, Chen X, Huang C, Yang L, Zhang W, et al. Optimizing CAR-T cell therapy for solid tumors: current challenges and potential strategies. J Hematol Oncol. 2024;17(1):105.","journal-title":"J Hematol Oncol"},{"issue":"5","key":"1746_CR25","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1182\/blood.V96.5.1999","volume":"96","author":"T Brocker","year":"2000","unstructured":"Brocker T. Chimeric Fv-zeta or Fv-epsilon receptors are not sufficient to induce activation or cytokine production in peripheral T cells. Blood. 2000;96(5):1999\u20132001.","journal-title":"Blood"},{"issue":"6","key":"1746_CR26","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1433518","volume":"7","author":"C Quintarelli","year":"2018","unstructured":"Quintarelli C, Orlando D, Boffa I, Guercio M, Polito VA, Petretto A, et al. Choice of costimulatory domains and of cytokines determines CAR T-cell activity in neuroblastoma. Oncoimmunology. 2018;7(6):e1433518.","journal-title":"Oncoimmunology"},{"issue":"1","key":"1746_CR27","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/s13045-021-01193-0","volume":"14","author":"N Tumino","year":"2021","unstructured":"Tumino N, Weber G, Besi F, Del Bufalo F, Bertaina V, Paci P, et al. Polymorphonuclear myeloid-derived suppressor cells impair the anti-tumor efficacy of GD2.CAR T-cells in patients with neuroblastoma. J Hematol Oncol. 2021;14(1):191.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"1746_CR28","doi-asserted-by":"publisher","first-page":"e96976","DOI":"10.1172\/jci.insight.96976","volume":"3","author":"S Guedan","year":"2018","unstructured":"Guedan S, Posey AD, Shaw C, Wing A, Da T, Patel PR, et al. Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation. JCI Insight. 2018;3(1):e96976. https:\/\/doi.org\/10.1172\/jci.insight.96976","journal-title":"JCI Insight"},{"issue":"17","key":"1746_CR29","doi-asserted-by":"publisher","first-page":"3940","DOI":"10.1182\/blood-2011-10-387969","volume":"119","author":"BG Till","year":"2012","unstructured":"Till BG, Jensen MC, Wang J, Qian X, Gopal AK, Maloney DG, et al. CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. Blood. 2012;119(17):3940\u201350.","journal-title":"Blood"},{"issue":"1","key":"1746_CR30","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s40364-023-00532-2","volume":"11","author":"F Korell","year":"2023","unstructured":"Korell F, Sch\u00f6nland S, Schmitt A, Jansen M, Farid K, M\u00fcller-Tidow C, et al. First third-generation CAR T cell application targeting CD19 for the treatment of systemic IgM AL amyloidosis with underlying marginal zone lymphoma. Biomark Res. 2023;11(1):91.","journal-title":"Biomark Res"},{"issue":"11","key":"1746_CR31","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1038\/s41587-023-02060-8","volume":"42","author":"Y Zhao","year":"2024","unstructured":"Zhao Y, Chen J, Andreatta M, Feng B, Xie Y-Q, Wenes M, et al. IL-10-expressing CAR T cells resist dysfunction and mediate durable clearance of solid tumors and metastases. Nat Biotechnol. 2024;42(11):1693\u2013704.","journal-title":"Nat Biotechnol"},{"issue":"1","key":"1746_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-024-00564-w","volume":"13","author":"X Li","year":"2024","unstructured":"Li X, Chen T, Li X, Zhang H, Li Y, Zhang S, et al. Therapeutic targets of armored chimeric antigen receptor T cells navigating the tumor microenvironment. Exp Hematol Oncol. 2024;13(1):96.","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"1746_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41421-023-00625-0","volume":"10","author":"W Lei","year":"2024","unstructured":"Lei W, Zhao A, Liu H, Yang C, Wei C, Guo S, et al. Safety and feasibility of anti-CD19 CAR T cells expressing inducible IL-7 and CCL19 in patients with relapsed or refractory large B-cell lymphoma. Cell Discov. 2024;10(1):5.","journal-title":"Cell Discov"},{"issue":"2","key":"1746_CR34","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1158\/1078-0432.CCR-20-1457","volume":"27","author":"H Liu","year":"2021","unstructured":"Liu H, Lei W, Zhang C, Yang C, Wei J, Guo Q, et al. CD19-specific CAR T cells that express a PD-1\/CD28 chimeric switch-receptor are effective in patients with PD-L1-positive B-cell lymphoma. Clin Cancer Res. 2021;27(2):473\u201384.","journal-title":"Clin Cancer Res"},{"issue":"17","key":"1746_CR35","doi-asserted-by":"publisher","first-page":"5697","DOI":"10.1158\/0008-5472.CAN-11-0103","volume":"71","author":"M Chmielewski","year":"2011","unstructured":"Chmielewski M, Kopecky C, Hombach AA, Abken H. IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression. Cancer Res. 2011;71(17):5697\u2013706.","journal-title":"Cancer Res"},{"issue":"7","key":"1746_CR36","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1038\/s41551-022-00875-5","volume":"6","author":"C Jin","year":"2022","unstructured":"Jin C, Ma J, Ramachandran M, Yu D, Essand M. CAR t cells expressing a bacterial virulence factor trigger potent bystander antitumour responses in solid cancers. Nat Biomed Eng. 2022;6(7):830\u201341.","journal-title":"Nat Biomed Eng"},{"issue":"2","key":"1746_CR37","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1038\/s41589-021-00932-1","volume":"18","author":"TJ Gardner","year":"2022","unstructured":"Gardner TJ, Lee JP, Bourne CM, Wijewarnasuriya D, Kinarivala N, Kurtz KG, et al. Engineering CAR-T cells to activate small-molecule drugs in situ. Nat Chem Biol. 2022;18(2):216\u201325.","journal-title":"Nat Chem Biol"},{"issue":"9","key":"1746_CR38","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1038\/nbt.4195","volume":"36","author":"S Rafiq","year":"2018","unstructured":"Rafiq S, Yeku OO, Jackson HJ, Purdon TJ, van Leeuwen DG, Drakes DJ, et al. Targeted delivery of a PD-1-blocking ScFv by CAR-T cells enhances anti-tumor efficacy in vivo. Nat Biotechnol. 2018;36(9):847\u201356.","journal-title":"Nat Biotechnol"},{"issue":"1","key":"1746_CR39","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.ccell.2021.12.005","volume":"40","author":"S Heitzeneder","year":"2022","unstructured":"Heitzeneder S, Bosse KR, Zhu Z, Zhelev D, Majzner RG, Radosevich MT, et al. GPC2-CAR T cells tuned for low antigen density mediate potent activity against neuroblastoma without toxicity. Cancer Cell. 2022;40(1):53\u201369.e9. https:\/\/doi.org\/10.1016\/j.ccell.2021.12.005","journal-title":"Cancer Cell"},{"issue":"1","key":"1746_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33793-w","volume":"13","author":"L Qin","year":"2022","unstructured":"Qin L, Cui Y, Yuan T, Chen D, Zhao R, Li S, et al. Co-expression of a PD-L1-specific chimeric switch receptor augments the efficacy and persistence of CAR T cells via the CD70-CD27 axis. Nat Commun. 2022;13(1):6051.","journal-title":"Nat Commun"},{"issue":"9","key":"1746_CR41","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/s43018-021-00244-2","volume":"2","author":"K Hirabayashi","year":"2021","unstructured":"Hirabayashi K, Du H, Xu Y, Shou P, Zhou X, Fuc\u00e1 G, et al. Dual targeting CAR-T cells with optimal costimulation and metabolic fitness enhance antitumor activity and prevent escape in solid tumors. Nat Cancer. 2021;2(9):904\u201318.","journal-title":"Nat Cancer"},{"issue":"623","key":"1746_CR42","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abh1962","volume":"13","author":"A Katsarou","year":"2021","unstructured":"Katsarou A, Sj\u00f6strand M, Naik J, Mansilla-Soto J, Kefala D, Kladis G, et al. Combining a CAR and a chimeric costimulatory receptor enhances T cell sensitivity to low antigen density and promotes persistence. Sci Transl Med. 2021;13(623):eabh1962.","journal-title":"Sci Transl Med"},{"issue":"3","key":"1746_CR43","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/nm.4478","volume":"24","author":"Y Kagoya","year":"2018","unstructured":"Kagoya Y, Tanaka S, Guo T, Anczurowski M, Wang C-H, Saso K, et al. A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects. Nat Med. 2018;24(3):352\u20139.","journal-title":"Nat Med"},{"key":"1746_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115691","volume":"168","author":"P Yuti","year":"2023","unstructured":"Yuti P, Sawasdee N, Natungnuy K, Rujirachaivej P, Luangwattananun P, Sujjitjoon J, et al. Enhanced antitumor efficacy, proliferative capacity, and alleviation of T cell exhaustion by fifth-generation chimeric antigen receptor T cells targeting B cell maturation antigen in multiple myeloma. Biomed Pharmacother. 2023;168:115691.","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"1746_CR45","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01301-8","volume":"15","author":"W-H Zhao","year":"2022","unstructured":"Zhao W-H, Wang B-Y, Chen L-J, Fu W-J, Xu J, Liu J, et al. Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multicenter study in China (LEGEND-2). J Hematol Oncol. 2022;15(1):86.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"1746_CR46","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s40164-024-00593-5","volume":"14","author":"T Yang","year":"2025","unstructured":"Yang T, Dong Y, Zhang M, Feng J, Fu S, Xiao P, et al. Prominent efficacy and good safety of sequential CD19 and CD22 CAR-T therapy in relapsed\/refractory adult B-cell acute lymphoblastic leukemia. Exp Hematol Oncol. 2025;14(1):2.","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"1746_CR47","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-024-01639-1","volume":"17","author":"H Huang","year":"2024","unstructured":"Huang H, Yu L, Weng H, Zhang W, Wang Z, Wang L. Advances in CAR-T cell therapy for hematologic and solid malignancies: latest updates from 2024 ESMO congress. J Hematol Oncol. 2024;17(1):120.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"1746_CR48","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-024-00573-9","volume":"13","author":"Y Yang","year":"2024","unstructured":"Yang Y, Peng H, Wang J, Li F. New insights into CAR T-cell hematological toxicities: manifestations, mechanisms, and effective management strategies. Exp Hematol Oncol. 2024;13(1):110.","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"1746_CR49","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-023-00482-9","volume":"11","author":"M Mazinani","year":"2023","unstructured":"Mazinani M, Rahbarizadeh F. New cell sources for CAR-based immunotherapy. Biomark Res. 2023;11(1):49.","journal-title":"Biomark Res"},{"issue":"1","key":"1746_CR50","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-024-01633-7","volume":"17","author":"W Zhang","year":"2024","unstructured":"Zhang W, Huang X. In vivo gene editing and in situ generation of chimeric antigen receptor cells for next-generation cancer immunotherapy. J Hematol Oncol. 2024;17(1):110.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"1746_CR51","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-024-00637-2","volume":"12","author":"J Lu","year":"2024","unstructured":"Lu J, Ma Y, Li Q, Xu Y, Xue Y, Xu S. CAR macrophages: a promising novel immunotherapy for solid tumors and beyond. Biomark Res. 2024;12(1):86.","journal-title":"Biomark Res"},{"issue":"7971","key":"1746_CR52","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1038\/s41586-023-06243-w","volume":"619","author":"DJ Baker","year":"2023","unstructured":"Baker DJ, Arany Z, Baur JA, Epstein JA, June CH. CAR T therapy beyond cancer: the evolution of a living drug. Nature. 2023;619(7971):707\u201315.","journal-title":"Nature"},{"issue":"9","key":"1746_CR53","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1038\/nri2395","volume":"8","author":"A Uccelli","year":"2008","unstructured":"Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol. 2008;8(9):726\u201336.","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"1746_CR54","first-page":"393","volume":"3","author":"AJ Friedenstein","year":"1970","unstructured":"Friedenstein AJ, Chailakhjan RK, Lalykina KS. The development of fibroblast colonies in monolayer cultures of guinea-pig bone marrow and spleen cells. Cell Tissue Kinet. 1970;3(4):393\u2013403.","journal-title":"Cell Tissue Kinet"},{"issue":"1","key":"1746_CR55","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-01134-4","volume":"7","author":"DM Hoang","year":"2022","unstructured":"Hoang DM, Pham PT, Bach TQ, Ngo ATL, Nguyen QT, Phan TTK, et al. Stem cell-based therapy for human diseases. Signal Transduct Target Ther. 2022;7(1):272.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"1746_CR56","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1186\/s13287-024-03968-x","volume":"15","author":"Z Wu","year":"2024","unstructured":"Wu Z, Su Y, Li J, Liu X, Liu Y, Zhao L, et al. Induced pluripotent stem cell-derived mesenchymal stem cells: whether they can become new stars of cell therapy. Stem Cell Res Ther. 2024;15(1):367.","journal-title":"Stem Cell Res Ther"},{"issue":"1","key":"1746_CR57","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1080\/21645515.2015.1030549","volume":"12","author":"Q Wang","year":"2016","unstructured":"Wang Q, Yang Q, Wang Z, Tong H, Ma L, Zhang Y, et al. Comparative analysis of human mesenchymal stem cells from fetal-bone marrow, adipose tissue, and Warton\u2019s jelly as sources of cell immunomodulatory therapy. Hum Vaccin Immunother. 2016;12(1):85\u201396.","journal-title":"Hum Vaccin Immunother"},{"issue":"4","key":"1746_CR58","doi-asserted-by":"publisher","DOI":"10.1007\/s13205-024-03966-z","volume":"14","author":"MS Poomani","year":"2024","unstructured":"Poomani MS, Regurajan R, Perumal R, Ramachandran A, Mariappan I, Muthan K, et al. Differentiation of placenta-derived MSCs cultured in human platelet lysate: a xenofree supplement. 3 Biotech. 2024;14(4):116.","journal-title":"3 Biotech"},{"issue":"13","key":"1746_CR59","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1242\/dev.134189","volume":"143","author":"PT Sharpe","year":"2016","unstructured":"Sharpe PT. Dental mesenchymal stem cells. Development. 2016;143(13):2273\u201380.","journal-title":"Development"},{"key":"1746_CR60","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.bpobgyn.2015.07.006","volume":"31","author":"MS Joerger-Messerli","year":"2016","unstructured":"Joerger-Messerli MS, Marx C, Oppliger B, Mueller M, Surbek DV, Schoeberlein A. Mesenchymal stem cells from Wharton\u2019s jelly and amniotic fluid. Best Pract Res Clin Obstet Gynaecol. 2016;31:30\u201344.","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"issue":"5","key":"1746_CR61","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1089\/ten.teb.2013.0664","volume":"20","author":"R El Omar","year":"2014","unstructured":"El Omar R, Beroud J, Stoltz J-F, Menu P, Velot E, Decot V. Umbilical cord mesenchymal stem cells: the new gold standard for mesenchymal stem cell-based therapies? Tissue Engineering Part B: Reviews. 2014;20(5):523\u201344.","journal-title":"Tissue Engineering Part B: Reviews"},{"issue":"4","key":"1746_CR62","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1080\/14653240600855905","volume":"8","author":"M Dominici","year":"2006","unstructured":"Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The international society for cellular therapy position statement. Cytotherapy. 2006;8(4):315\u20137.","journal-title":"Cytotherapy"},{"issue":"11","key":"1746_CR63","doi-asserted-by":"publisher","first-page":"2637","DOI":"10.1177\/0363546517706138","volume":"45","author":"N Topoluk","year":"2017","unstructured":"Topoluk N, Hawkins R, Tokish J, Mercuri J. Amniotic mesenchymal stromal cells exhibit preferential osteogenic and chondrogenic differentiation and enhanced matrix production compared with adipose mesenchymal stromal cells. Am J Sports Med. 2017;45(11):2637\u201346.","journal-title":"Am J Sports Med"},{"issue":"3","key":"1746_CR64","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s00441-006-0308-z","volume":"327","author":"H Yoshimura","year":"2007","unstructured":"Yoshimura H, Muneta T, Nimura A, Yokoyama A, Koga H, Sekiya I. Comparison of rat mesenchymal stem cells derived from bone marrow, synovium, periosteum, adipose tissue, and muscle. Cell Tissue Res. 2007;327(3):449\u201362.","journal-title":"Cell Tissue Res"},{"issue":"1","key":"1746_CR65","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-05294-5","volume":"22","author":"S Chen","year":"2024","unstructured":"Chen S, Liang B, Xu J. Unveiling heterogeneity in MSCs: exploring marker-based strategies for defining MSC subpopulations. J Transl Med. 2024;22(1):459.","journal-title":"J Transl Med"},{"key":"1746_CR66","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.637239","volume":"9","author":"Q Li","year":"2021","unstructured":"Li Q, Hou H, Li M, Yu X, Zuo H, Gao J, et al. CD73\u2009+\u2009mesenchymal stem cells ameliorate myocardial infarction by promoting angiogenesis. Front Cell Dev Biol. 2021;9:637239.","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"1746_CR67","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-021-02177-0","volume":"12","author":"RJP Smith","year":"2021","unstructured":"Smith RJP, Faroni A, Barrow JR, Soul J, Reid AJ. The angiogenic potential of CD271\u2009+\u2009human adipose tissue-derived mesenchymal stem cells. Stem Cell Res Ther. 2021;12(1):160.","journal-title":"Stem Cell Res Ther"},{"issue":"1","key":"1746_CR68","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-022-03176-5","volume":"13","author":"L Li","year":"2022","unstructured":"Li L, Yang L, Chen X, Chen X, Diao L, Zeng Y, et al. TNFAIP6 defines the MSC subpopulation with enhanced immune suppression activities. Stem Cell Res Ther. 2022;13(1):479.","journal-title":"Stem Cell Res Ther"},{"issue":"1","key":"1746_CR69","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-024-03817-x","volume":"15","author":"D Hu","year":"2024","unstructured":"Hu D, Lai J, Chen Q, Bai L. New advances of NG2-expressing cell subset in marrow mesenchymal stem cells as novel therapeutic tools for liver fibrosis\/cirrhosis. Stem Cell Res Ther. 2024;15(1):199.","journal-title":"Stem Cell Res Ther"},{"issue":"10","key":"1746_CR70","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.13300","volume":"55","author":"Y Jia","year":"2022","unstructured":"Jia Y, Wang A, Zhao B, Wang C, Su R, Zhang B, et al. An optimized method for obtaining clinical-grade specific cell subpopulations from human umbilical cord-derived mesenchymal stem cells. Cell Prolif. 2022;55(10):e13300.","journal-title":"Cell Prolif"},{"issue":"1","key":"1746_CR71","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13287-023-03618-8","volume":"15","author":"J Song","year":"2024","unstructured":"Song J, Ma Q, Li Y, Wang X, Chen S, Liang B, et al. CD317\u2009+\u2009MSCs expanded with chemically defined media have enhanced immunological anti-inflammatory activities. Stem Cell Res Ther. 2024;15(1):2.","journal-title":"Stem Cell Res Ther"},{"key":"1746_CR72","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-016-0285-4","volume":"7","author":"C-C Wu","year":"2016","unstructured":"Wu C-C, Liu F-L, Sytwu H-K, Tsai C-Y, Chang D-M. CD146\u2009+\u2009mesenchymal stem cells display greater therapeutic potential than CD146- cells for treating collagen-induced arthritis in mice. Stem Cell Res Ther. 2016;7:23.","journal-title":"Stem Cell Res Ther"},{"issue":"15","key":"1746_CR73","doi-asserted-by":"publisher","first-page":"13723","DOI":"10.1074\/jbc.M110.144691","volume":"286","author":"C Zhang","year":"2011","unstructured":"Zhang C, Chen X-H, Zhang X, Gao L, Kong P-Y, Peng X-g, et al. Human umbilical cord blood-derived stromal cells, a new resource in the suppression of acute graft-versus-host disease in haploidentical stem cell transplantation in sublethally irradiated mice. J Biol Chem. 2011;286(15):13723\u201332.","journal-title":"J Biol Chem"},{"issue":"24","key":"1746_CR74","doi-asserted-by":"publisher","first-page":"2843","DOI":"10.1200\/JCO.2015.65.3642","volume":"34","author":"L Gao","year":"2016","unstructured":"Gao L, Zhang Y, Hu B, Liu J, Kong P, Lou S, et al. Phase II multicenter, randomized, double-blind controlled study of efficacy and safety of umbilical cord-derived mesenchymal stromal cells in the prophylaxis of chronic graft-versus-host disease after HLA-haploidentical stem-cell transplantation. J Clin Oncol. 2016;34(24):2843\u201350.","journal-title":"J Clin Oncol"},{"key":"1746_CR75","doi-asserted-by":"publisher","unstructured":"Zhang C, Chen X-H, Zhang X, Gao L, Gao L, Kong P-Y, et al. Regulation of acute graft-versus-host disease by human umbilical cord blood derived stromal cells in haploidentical stem cell transplantation in mice through very late activation antigen-4. Clin Immunol. 2011;101. https:\/\/doi.org\/10.1016\/j.clim.2011.01.004.","DOI":"10.1016\/j.clim.2011.01.004"},{"issue":"3","key":"1746_CR76","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s12013-011-9328-8","volume":"62","author":"C Zhang","year":"2012","unstructured":"Zhang C, Zhang X, Chen X-H. Hypothesis: human umbilical cord blood-derived stromal cells regulate the Foxp3 expression of regulatory T cells through the TGF-\u03b21\/Smad3 pathway. Cell Biochem Biophys. 2012;62(3):463\u20136.","journal-title":"Cell Biochem Biophys"},{"key":"1746_CR77","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1528478","volume":"15","author":"M Gurrea-Rubio","year":"2024","unstructured":"Gurrea-Rubio M, Lin F, Wicha MS, Mao-Draayer Y, Fox DA. Ligands of CD6: roles in the pathogenesis and treatment of cancer. Front Immunol. 2024;15:1528478.","journal-title":"Front Immunol"},{"issue":"1","key":"1746_CR78","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-023-03594-1","volume":"73","author":"R Towers","year":"2024","unstructured":"Towers R, Trombello L, Fusenig M, Tunger A, Baumann A-L, Savoldelli R, et al. Bone marrow-derived mesenchymal stromal cells obstruct AML-targeting CD8\u2009+\u2009clonal effector and CAR T-cell function while promoting a senescence-associated phenotype. Cancer Immunol Immunother. 2024;73(1):8.","journal-title":"Cancer Immunol Immunother"},{"key":"1746_CR79","doi-asserted-by":"publisher","first-page":"e82934","DOI":"10.7554\/eLife.82934","volume":"12","author":"R Zhang","year":"2023","unstructured":"Zhang R, Liu Q, Zhou S, He H, Zhao M, Ma W. Mesenchymal stem cell suppresses the efficacy of CAR-T toward killing lymphoma cells by modulating the microenvironment through stanniocalcin-1. Elife. 2023;12:e82934. https:\/\/doi.org\/10.7554\/eLife.82934","journal-title":"Elife"},{"issue":"13","key":"1746_CR80","doi-asserted-by":"publisher","first-page":"3793","DOI":"10.1158\/1078-0432.CCR-20-2188","volume":"27","author":"LC Holthof","year":"2021","unstructured":"Holthof LC, van der Schans JJ, Katsarou A, Poels R, Gelderloos AT, Drent E, et al. Bone marrow mesenchymal stromal cells can render multiple myeloma cells resistant to cytotoxic machinery of CAR T cells through inhibition of apoptosis. Clin Cancer Res. 2021;27(13):3793\u2013803.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"1746_CR81","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000561","volume":"5","author":"LC Holthof","year":"2021","unstructured":"Holthof LC, Stikvoort A, van der Horst HJ, Gelderloos AT, Poels R, Li F, et al. Bone marrow mesenchymal stromal cell-mediated resistance in multiple myeloma against NK cells can be overcome by introduction of CD38-CAR or TRAIL-variant. Hemasphere. 2021;5(5):e561.","journal-title":"Hemasphere"},{"issue":"1","key":"1746_CR82","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-05627-4","volume":"22","author":"AC Court","year":"2024","unstructured":"Court AC, Parra-Cris\u00f3stomo E, Castro-C\u00f3rdova P, Abdo L, Arag\u00e3o EAA, Lorca R, et al. Survival advantage of native and engineered T cells is acquired by mitochondrial transfer from mesenchymal stem cells. J Transl Med. 2024;22(1):868.","journal-title":"J Transl Med"},{"issue":"5","key":"1746_CR83","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1016\/j.ymthe.2021.02.004","volume":"29","author":"MK McKenna","year":"2021","unstructured":"McKenna MK, Englisch A, Brenner B, Smith T, Hoyos V, Suzuki M, et al. Mesenchymal stromal cell delivery of oncolytic immunotherapy improves CAR-T cell antitumor activity. Mol Ther. 2021;29(5):1808\u201320.","journal-title":"Mol Ther"},{"issue":"4","key":"1746_CR84","doi-asserted-by":"publisher","first-page":"873","DOI":"10.3390\/cells9040873","volume":"9","author":"AA Hombach","year":"2020","unstructured":"Hombach AA, Geumann U, G\u00fcnther C, Hermann FG, Abken H. IL7-IL12 engineered mesenchymal stem cells (MSCs) improve a CAR T cell attack against colorectal cancer cells. Cells. 2020;9(4):873. https:\/\/doi.org\/10.3390\/cells9040873","journal-title":"Cells"},{"issue":"2","key":"1746_CR85","doi-asserted-by":"publisher","first-page":"e001419","DOI":"10.1136\/jitc-2020-001419","volume":"8","author":"SR Zanetti","year":"2020","unstructured":"Zanetti SR, Romecin PA, Vinyoles M, Juan M, Fuster JL, C\u00e1mos M, et al. Bone marrow MSC from pediatric patients with B-ALL highly immunosuppress T-cell responses but do not compromise CD19-CAR T-cell activity. J Immunother Cancer. 2020;8(2):e001419. https:\/\/doi.org\/10.1136\/jitc-2020-001419","journal-title":"J Immunother Cancer"},{"issue":"1","key":"1746_CR86","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1186\/s13287-024-03941-8","volume":"15","author":"Y Xia","year":"2024","unstructured":"Xia Y, Wang L, Shen X, Xu Y, Xu W, Li J, et al. Mesenchymal stem cell infusion for enhancing hematopoietic recovery and addressing cytopenias in CAR-T cell therapy. Stem Cell Res Ther. 2024;15(1):333.","journal-title":"Stem Cell Res Ther"},{"issue":"1","key":"1746_CR87","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-024-00580-2","volume":"12","author":"A Hazrati","year":"2024","unstructured":"Hazrati A, Malekpour K, Khorramdelazad H, Rajaei S, Hashemi SM. Therapeutic and immunomodulatory potentials of mesenchymal stromal\/stem cells and immune checkpoints related molecules. Biomark Res. 2024;12(1):35.","journal-title":"Biomark Res"},{"issue":"6","key":"1746_CR88","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/s41423-023-01034-9","volume":"20","author":"J Zhou","year":"2023","unstructured":"Zhou J, Shi Y. Mesenchymal stem\/stromal cells (MSCs): origin, immune regulation, and clinical applications. Cell Mol Immunol. 2023;20(6):555\u20137.","journal-title":"Cell Mol Immunol"},{"issue":"1","key":"1746_CR89","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01737-7","volume":"22","author":"Y Zhou","year":"2023","unstructured":"Zhou Y, Cheng L, Liu L, Li X. NK cells are never alone: crosstalk and communication in tumour microenvironments. Mol Cancer. 2023;22(1):34.","journal-title":"Mol Cancer"},{"issue":"12","key":"1746_CR90","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/j.imbio.2018.08.002","volume":"223","author":"F Salami","year":"2018","unstructured":"Salami F, Tavassoli A, Mehrzad J, Parham A. Immunomodulatory effects of mesenchymal stem cells on leukocytes with emphasis on neutrophils. Immunobiology. 2018;223(12):786\u201391.","journal-title":"Immunobiology"},{"issue":"1","key":"1746_CR91","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-023-03277-9","volume":"14","author":"K Hezam","year":"2023","unstructured":"Hezam K, Wang C, Fu E, Zhou M, Liu Y, Wang H, et al. Superior protective effects of PGE2 priming mesenchymal stem cells against LPS-induced acute lung injury (ALI) through macrophage immunomodulation. Stem Cell Res Ther. 2023;14(1):48.","journal-title":"Stem Cell Res Ther"},{"key":"1746_CR92","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.217264","volume":"605","author":"Y Wang","year":"2024","unstructured":"Wang Y, Chang Y-J, Chen J, Han M, Hu J, Hu J, et al. Consensus on the monitoring, treatment, and prevention of leukaemia relapse after allogeneic haematopoietic stem cell transplantation in China: 2024 update. Cancer Lett. 2024;605:217264.","journal-title":"Cancer Lett"},{"issue":"1","key":"1746_CR93","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01159-2","volume":"14","author":"X-H Zhang","year":"2021","unstructured":"Zhang X-H, Chen J, Han M-Z, Huang H, Jiang E-L, Jiang M, et al. The consensus from the Chinese society of hematology on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell transplantation: 2021 update. J Hematol Oncol. 2021;14(1):145.","journal-title":"J Hematol Oncol"},{"key":"1746_CR94","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2022.215721","volume":"549","author":"R Huang","year":"2022","unstructured":"Huang R, Wang X, Zhang X. Unity brings strength: combination of CAR-T cell therapy and HSCT. Cancer Lett. 2022;549:215721.","journal-title":"Cancer Lett"},{"issue":"2","key":"1746_CR95","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1001\/jamaoncol.2023.5757","volume":"10","author":"R Huang","year":"2024","unstructured":"Huang R, Chen T, Wang S, Wang J, Su Y, Liu J, et al. Mesenchymal stem cells for prophylaxis of chronic graft-vs-host disease after haploidentical hematopoietic stem cell transplant: an open-label randomized clinical trial. JAMA Oncol. 2024;10(2):220\u20136.","journal-title":"JAMA Oncol"},{"issue":"1","key":"1746_CR96","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01240-4","volume":"15","author":"K Zhao","year":"2022","unstructured":"Zhao K, Lin R, Fan Z, Chen X, Wang Y, Huang F, et al. Mesenchymal stromal cells plus basiliximab, calcineurin inhibitor as treatment of steroid-resistant acute graft-versus-host disease: a multicenter, randomized, phase 3, open-label trial. J Hematol Oncol. 2022;15(1):22.","journal-title":"J Hematol Oncol"},{"issue":"6","key":"1746_CR97","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1038\/s41591-024-02990-z","volume":"30","author":"K Kelly","year":"2024","unstructured":"Kelly K, Bloor AJC, Griffin JE, Radia R, Yeung DT, Rasko JEJ. Two-year safety outcomes of iPS cell-derived mesenchymal stromal cells in acute steroid-resistant graft-versus-host disease. Nat Med. 2024;30(6):1556\u20138.","journal-title":"Nat Med"},{"issue":"1","key":"1746_CR98","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1186\/s12916-024-03782-5","volume":"22","author":"E Jiang","year":"2024","unstructured":"Jiang E, Qian K, Wang L, Yang D, Shao Y, Hu L, et al. Efficacy and safety of human umbilical cord-derived mesenchymal stem cells versus placebo added to second-line therapy in patients with steroid-refractory acute graft-versus-host disease: a multicentre, randomized, double-blind, phase 2 trial. BMC Med. 2024;22(1):555.","journal-title":"BMC Med"},{"issue":"4","key":"1746_CR99","doi-asserted-by":"publisher","first-page":"e261","DOI":"10.1016\/S2665-9913(24)00298-4","volume":"7","author":"D Farge","year":"2025","unstructured":"Farge D, Biard L, Weil B, Girault V, Lansiaux P, Munia I, et al. Allogeneic umbilical cord-derived mesenchymal stromal cells as treatment for systemic lupus erythematosus: a single-centre, open-label, dose-escalation, phase 1 study. Lancet Rheumatol. 2025;7(4):e261\u201373.","journal-title":"Lancet Rheumatol"},{"issue":"1","key":"1746_CR100","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-024-03765-6","volume":"15","author":"VK Harris","year":"2024","unstructured":"Harris VK, Stark J, Williams A, Roche M, Malin M, Kumar A, et al. Efficacy of intrathecal mesenchymal stem cell-neural progenitor therapy in progressive MS: results from a phase II, randomized, placebo-controlled clinical trial. Stem Cell Res Ther. 2024;15(1):151.","journal-title":"Stem Cell Res Ther"},{"issue":"4","key":"1746_CR101","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/j.jaci.2024.06.013","volume":"154","author":"H-M Seo","year":"2024","unstructured":"Seo H-M, Lew B-L, Lee YW, Son SW, Park CO, Park YL, et al. Phase 1\/2 trials of human bone marrow-derived clonal mesenchymal stem cells for treatment of adults with moderate to severe atopic dermatitis. J Allergy Clin Immunol. 2024;154(4):965\u201373.","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"1746_CR102","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1093\/ecco-jcc\/jjac192","volume":"17","author":"C Reenaers","year":"2023","unstructured":"Reenaers C, Gillard RP, Coimbra C, Gillard RM, Meunier P, Lechanteur C, et al. Clinical and MRI evolution after local injection of bone marrow-derived mesenchymal stem cells in perianal fistulae in Crohn\u2019s disease: results from a prospective monocentric study. J Crohns Colitis. 2023;17(5):728\u201337.","journal-title":"J Crohns Colitis"},{"issue":"4","key":"1746_CR103","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/s41551-024-01195-6","volume":"8","author":"O Sirpilla","year":"2024","unstructured":"Sirpilla O, Sakemura RL, Hefazi M, Huynh TN, Can I, Girsch JH, et al. Mesenchymal stromal cells with chimaeric antigen receptors for enhanced immunosuppression. Nat Biomed Eng. 2024;8(4):443\u201360.","journal-title":"Nat Biomed Eng"},{"issue":"2","key":"1746_CR104","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.critrevonc.2013.12.002","volume":"90","author":"S-S Liu","year":"2014","unstructured":"Liu S-S, Zhang C, Zhang X, Chen X-H. Human umbilical cord blood-derived stromal cells: a new source of stromal cells in hematopoietic stem cell transplantation. Crit Rev Oncol Hematol. 2014;90(2):93\u20138.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"2","key":"1746_CR105","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.mehy.2010.10.008","volume":"76","author":"C Zhang","year":"2011","unstructured":"Zhang C, Zhang X, Chen X-H. Granulocyte-colony stimulating factor-mobilized mesenchymal stem cells: a new resource for rapid engraftment in hematopoietic stem cell transplantation. Med Hypotheses. 2011;76(2):241\u20133.","journal-title":"Med Hypotheses"},{"issue":"1","key":"1746_CR106","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-025-03987-2","volume":"23","author":"T-S Tai","year":"2025","unstructured":"Tai T-S, Chen Y-H, Yao C-L, Lin J-H, Yang Y-S, Shi J-W, et al. Cellular sentinels: empowering survival and immune defense in hematopoietic stem cell transplantation through mesenchymal stem cells and T lymphocytes. BMC Med. 2025;23(1):164.","journal-title":"BMC Med"},{"issue":"1","key":"1746_CR107","doi-asserted-by":"publisher","DOI":"10.1186\/s40001-023-01244-x","volume":"28","author":"T Lin","year":"2023","unstructured":"Lin T, Yang Y, Chen X. A review of the application of mesenchymal stem cells in the field of hematopoietic stem cell transplantation. Eur J Med Res. 2023;28(1):268.","journal-title":"Eur J Med Res"},{"issue":"1","key":"1746_CR108","doi-asserted-by":"publisher","DOI":"10.1186\/s12887-021-02562-x","volume":"21","author":"Y Lan","year":"2021","unstructured":"Lan Y, Liu F, Chang L, Liu L, Zhang Y, Yi M, et al. Combination of umbilical cord mesenchymal stem cells and standard immunosuppressive regimen for pediatric patients with severe aplastic anemia. BMC Pediatr. 2021;21(1):102.","journal-title":"BMC Pediatr"},{"issue":"1","key":"1746_CR109","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01793-5","volume":"9","author":"Y Chen","year":"2024","unstructured":"Chen Y, Xu Y, Chi Y, Sun T, Gao Y, Dou X, et al. Efficacy and safety of human umbilical cord-derived mesenchymal stem cells in the treatment of refractory immune thrombocytopenia: a prospective, single arm, phase I trial. Signal Transduct Target Ther. 2024;9(1):102.","journal-title":"Signal Transduct Target Ther"},{"key":"1746_CR110","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241914484","volume":"24","author":"W Xu","year":"2023","unstructured":"Xu W, Yang Y, Li N, Hua J. Interaction between mesenchymal stem cells and immune cells during bone injury repair. Int J Mol Sci. 2023;24:19.","journal-title":"Int J Mol Sci"},{"key":"1746_CR111","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2024.122720","volume":"312","author":"C Wu","year":"2025","unstructured":"Wu C, Huang Z, Chen J, Li N, Cai Y, Chen J, et al. Efficiently directing differentiation and homing of mesenchymal stem cells to boost cartilage repair in osteoarthritis via a nanoparticle and peptide dual-engineering strategy. Biomaterials. 2025;312:122720.","journal-title":"Biomaterials"},{"issue":"1","key":"1746_CR112","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-023-03431-3","volume":"14","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Ju W, Zhang H, Mengyun L, Shen W, Chen X. Mechanisms and therapeutic prospects of mesenchymal stem cells-derived exosomes for tendinopathy. Stem Cell Res Ther. 2023;14(1):307.","journal-title":"Stem Cell Res Ther"},{"key":"1746_CR113","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2023.108563","volume":"253","author":"P Yadav","year":"2024","unstructured":"Yadav P, Singh SK, Rajput S, Allawadhi P, Khurana A, Weiskirchen R, et al. Therapeutic potential of stem cells in regeneration of liver in chronic liver diseases: current perspectives and future challenges. Pharmacol Ther. 2024;253:108563.","journal-title":"Pharmacol Ther"},{"key":"1746_CR114","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2023.102871","volume":"67","author":"S Yao","year":"2023","unstructured":"Yao S, Pang M, Wang Y, Wang X, Lin Y, Lv Y, et al. Mesenchymal stem cell attenuates spinal cord injury by inhibiting mitochondrial quality control-associated neuronal ferroptosis. Redox Biol. 2023;67:102871.","journal-title":"Redox Biol"},{"issue":"1","key":"1746_CR115","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-025-04233-5","volume":"16","author":"S Sajadi","year":"2025","unstructured":"Sajadi S, Khadembashiri MA, Raissi G, Khadembashiri MM, Mansouri K, Hadizadeh-Kharazi H, et al. The role of adipose-derived stem cells in knee osteoarthritis treatment: insights from a triple-blind clinical study. Stem Cell Res Ther. 2025;16(1):242.","journal-title":"Stem Cell Res Ther"},{"key":"1746_CR116","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.yjmcc.2023.12.009","volume":"188","author":"W Yan","year":"2024","unstructured":"Yan W, Xia Y, Zhao H, Xu X, Ma X, Tao L. Stem cell-based therapy in cardiac repair after myocardial infarction: promise, challenges, and future directions. J Mol Cell Cardiol. 2024;188:1\u201314. https:\/\/doi.org\/10.1016\/j.yjmcc.2023.12.009","journal-title":"J Mol Cell Cardiol"},{"issue":"1","key":"1746_CR117","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-023-03495-1","volume":"14","author":"A Attar","year":"2023","unstructured":"Attar A, Farjoud Kouhanjani M, Hessami K, Vosough M, Kojuri J, Ramzi M, et al. Effect of once versus twice intracoronary injection of allogeneic-derived mesenchymal stromal cells after acute myocardial infarction: BOOSTER-TAHA7 randomized clinical trial. Stem Cell Res Ther. 2023;14(1):264.","journal-title":"Stem Cell Res Ther"},{"issue":"4","key":"1746_CR118","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1002\/ejhf.2772","volume":"25","author":"AA Qayyum","year":"2023","unstructured":"Qayyum AA, van Klarenbosch B, Frljak S, Cerar A, Poglajen G, Traxler-Weidenauer D, et al. Effect of allogeneic adipose tissue-derived mesenchymal stromal cell treatment in chronic ischaemic heart failure with reduced ejection fraction - the SCIENCE trial. Eur J Heart Fail. 2023;25(4):576\u201387.","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"1746_CR119","volume":"10","author":"J-Y Ding","year":"2023","unstructured":"Ding J-Y, Chen M-J, Wu L-F, Shu G-F, Fang S-J, Li Z-Y, et al. Mesenchymal stem cell-derived extracellular vesicles in skin wound healing: roles, opportunities and challenges. Mil Med Res. 2023;10(1):36.","journal-title":"Mil Med Res"},{"issue":"1","key":"1746_CR120","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-023-03390-9","volume":"14","author":"Z Shirbaghaee","year":"2023","unstructured":"Shirbaghaee Z, Heidari Keshel S, Rasouli M, Valizadeh M, Hashemi Nazari SS, Hassani M, et al. Report of a phase 1 clinical trial for safety assessment of human placental mesenchymal stem cells therapy in patients with critical limb ischemia (CLI). Stem Cell Res Ther. 2023;14(1):174.","journal-title":"Stem Cell Res Ther"},{"issue":"4","key":"1746_CR121","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1038\/s41591-025-03559-0","volume":"31","author":"BG Rash","year":"2025","unstructured":"Rash BG, Ramdas KN, Agafonova N, Naioti E, McClain-Moss L, Zainul Z, et al. Allogeneic mesenchymal stem cell therapy with laromestrocel in mild Alzheimer\u2019s disease: a randomized controlled phase 2a trial. Nat Med. 2025;31(4):1257\u201366.","journal-title":"Nat Med"},{"issue":"1","key":"1746_CR122","volume":"11","author":"Y Zhuo","year":"2024","unstructured":"Zhuo Y, Li W-S, Lu W, Li X, Ge L-T, Huang Y, et al. TGF-\u03b21 mediates hypoxia-preconditioned olfactory mucosa mesenchymal stem cells improved neural functional recovery in parkinson\u2019s disease models and patients. Mil Med Res. 2024;11(1):48.","journal-title":"Mil Med Res"},{"key":"1746_CR123","first-page":"16","volume":"29","author":"L Giovannelli","year":"2023","unstructured":"Giovannelli L, Bari E, Jommi C, Tartara F, Armocida D, Garbossa D, et al. Mesenchymal stem cell secretome and extracellular vesicles for neurodegenerative diseases: risk-benefit profile and next steps for the market access. Bioact Mater. 2023;29:16\u201335.","journal-title":"Bioact Mater"},{"issue":"1","key":"1746_CR124","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1161\/STROKEAHA.121.034505","volume":"53","author":"J Lee","year":"2022","unstructured":"Lee J, Chang WH, Chung J-W, Kim SJ, Kim S-K, Lee JS, et al. Efficacy of intravenous mesenchymal stem cells for motor recovery after ischemic stroke: a neuroimaging study. Stroke. 2022;53(1):20\u20138.","journal-title":"Stroke"},{"issue":"6","key":"1746_CR125","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/S1474-4422(22)00117-X","volume":"21","author":"LM Baak","year":"2022","unstructured":"Baak LM, Wagenaar N, van der Aa NE, Groenendaal F, Dudink J, Tataranno ML, et al. Feasibility and safety of intranasally administered mesenchymal stromal cells after perinatal arterial ischaemic stroke in the Netherlands (PASSIoN): a first-in-human, open-label intervention study. Lancet Neurol. 2022;21(6):528\u201336.","journal-title":"Lancet Neurol"},{"issue":"1","key":"1746_CR126","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s12028-023-01897-w","volume":"41","author":"NC Durand","year":"2024","unstructured":"Durand NC, Kim HG, Patel VN, Turnbull MT, Siegel JL, Hodge DO, et al. Mesenchymal stem cell therapy in acute intracerebral hemorrhage: a dose-escalation safety and tolerability trial. Neurocrit Care. 2024;41(1):59\u201369.","journal-title":"Neurocrit Care"},{"issue":"7","key":"1746_CR127","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000209797","volume":"103","author":"DO Okonkwo","year":"2024","unstructured":"Okonkwo DO, McAllister P, Achrol AS, Karasawa Y, Kawabori M, Cramer SC, et al. Mesenchymal stromal cell implants for chronic motor deficits after traumatic brain injury: post hoc analysis of a randomized trial. Neurology. 2024;103(7):e209797.","journal-title":"Neurology"},{"issue":"1","key":"1746_CR128","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-023-03500-7","volume":"14","author":"JC Pastor","year":"2023","unstructured":"Pastor JC, Pastor-Idoate S, L\u00f3pez-Paniagua M, Para M, Blazquez F, Murgui E, et al. Intravitreal allogeneic mesenchymal stem cells: a non-randomized phase II clinical trial for acute non-arteritic optic neuropathy. Stem Cell Res Ther. 2023;14(1):261.","journal-title":"Stem Cell Res Ther"},{"issue":"3","key":"1746_CR129","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1002\/sctm.18-0117","volume":"8","author":"S Fran\u00e7ois","year":"2019","unstructured":"Fran\u00e7ois S, Usunier B, Forgue-Lafitte M-E, L\u2019Homme B, Benderitter M, Douay L, et al. Mesenchymal stem cell administration attenuates colon cancer progression by modulating the immune component within the colorectal tumor microenvironment. Stem Cells Transl Med. 2019;8(3):285\u2013300.","journal-title":"Stem Cells Transl Med"},{"key":"1746_CR130","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-016-0062-1","volume":"6","author":"N-DP Vanegas","year":"2017","unstructured":"Vanegas N-DP, Vernot J-P. Loss of quiescence and self-renewal capacity of hematopoietic stem cell in an in vitro leukemic niche. Exp Hematol Oncol. 2017;6:2.","journal-title":"Exp Hematol Oncol"},{"issue":"3","key":"1746_CR131","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s10561-019-09781-8","volume":"20","author":"M Mirabdollahi","year":"2019","unstructured":"Mirabdollahi M, Haghjooyjavanmard S, Sadeghi-Aliabadi H. An anticancer effect of umbilical cord-derived mesenchymal stem cell secretome on the breast cancer cell line. Cell Tissue Bank. 2019;20(3):423\u201334.","journal-title":"Cell Tissue Bank"},{"key":"1746_CR132","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.reth.2024.08.008","volume":"26","author":"R Farahzadi","year":"2024","unstructured":"Farahzadi R, Fathi E, Vandghanooni S, Valipour B. Cytokines secreted from bone marrow-derived mesenchymal stem cells promote apoptosis of CD34\u2009+\u2009leukemic stem cells as anti-cancer therapy. Regen Ther. 2024;26:646\u201353.","journal-title":"Regen Ther"},{"issue":"8","key":"1746_CR133","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.3390\/ijms19082188","volume":"19","author":"KS Fakiruddin","year":"2018","unstructured":"Fakiruddin KS, Ghazalli N, Lim MN, Zakaria Z, Abdullah S. Mesenchymal stem cell expressing TRAIL as targeted therapy against sensitised tumour. Int J Mol Sci. 2018;19(8):2188.","journal-title":"Int J Mol Sci"},{"issue":"9","key":"1746_CR134","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1002\/ijc.31599","volume":"143","author":"FR Stefani","year":"2018","unstructured":"Stefani FR, Eberst\u00e5l S, Vergani S, Kristiansen TA, Bengzon J. Low-dose irradiated mesenchymal stromal cells break tumor defensive properties in vivo. Int J Cancer. 2018;143(9):2200\u201312.","journal-title":"Int J Cancer"},{"issue":"10","key":"1746_CR135","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.2174\/011574888X287102240101060146","volume":"19","author":"Y Zhou","year":"2024","unstructured":"Zhou Y, Li Y, Wang H, Sun H, Su J, Fan Y, et al. Mesenchymal stem cells target gastric cancer and deliver epirubicin via tunneling nanotubes for enhanced chemotherapy. Curr Stem Cell Res Ther. 2024;19(10):1402\u201313.","journal-title":"Curr Stem Cell Res Ther"},{"issue":"10","key":"1746_CR136","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.7150\/ijms.25760","volume":"15","author":"S Kalimuthu","year":"2018","unstructured":"Kalimuthu S, Zhu L, Oh JM, Gangadaran P, Lee HW, Baek SH, et al. Migration of mesenchymal stem cells to tumor xenograft models and in vitro drug delivery by doxorubicin. Int J Med Sci. 2018;15(10):1051\u201361.","journal-title":"Int J Med Sci"},{"issue":"7","key":"1746_CR137","doi-asserted-by":"publisher","DOI":"10.3390\/biom14070734","volume":"14","author":"JI Gil-Chinchilla","year":"2024","unstructured":"Gil-Chinchilla JI, Zapata AG, Moraleda JM, Garc\u00eda-Bernal D. Bioengineered mesenchymal stem\/stromal cells in anti-cancer therapy: current trends and future prospects. Biomolecules. 2024;14(7):734.","journal-title":"Biomolecules"},{"key":"1746_CR138","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2022.215661","volume":"535","author":"W Liu","year":"2022","unstructured":"Liu W, Wang X, Feng X, Yu J, Liu X, Jia X, et al. Oncolytic adenovirus-mediated intratumoral expression of TRAIL and CD40L enhances immunotherapy by modulating the tumor microenvironment in immunocompetent mouse models. Cancer Lett. 2022;535:215661.","journal-title":"Cancer Lett"},{"issue":"1","key":"1746_CR139","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-023-04213-4","volume":"21","author":"S Oraee-Yazdani","year":"2023","unstructured":"Oraee-Yazdani S, Tavanaei R, Rostami F, Hajarizadeh A, Mehrabadi M, Akhlaghpasand M, et al. Suicide gene therapy using allogeneic adipose tissue-derived mesenchymal stem cell gene delivery vehicles in recurrent glioblastoma multiforme: a first-in-human, dose-escalation, phase I clinical trial. J Transl Med. 2023;21(1):350.","journal-title":"J Transl Med"},{"issue":"1","key":"1746_CR140","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-024-03907-w","volume":"15","author":"Z Wu","year":"2024","unstructured":"Wu Z, Huang S, Li S, Cai J, Huang L, Wu W, et al. Bone marrow mesenchymal stem cell and mononuclear cell combination therapy in patients with type 2 diabetes mellitus: a randomized controlled study with 8-year follow-up. Stem Cell Res Ther. 2024;15(1):339.","journal-title":"Stem Cell Res Ther"},{"issue":"10","key":"1746_CR141","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1681\/ASN.0000000000000189","volume":"34","author":"N Perico","year":"2023","unstructured":"Perico N, Remuzzi G, Griffin MD, Cockwell P, Maxwell AP, Casiraghi F, et al. Safety and preliminary efficacy of mesenchymal stromal cell (ORBCEL-M) therapy in diabetic kidney disease: a randomized clinical trial (NEPHSTROM). J Am Soc Nephrol. 2023;34(10):1733\u201351.","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"1746_CR142","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1186\/s13287-023-03427-z","volume":"14","author":"ML Arango-Rodr\u00edguez","year":"2023","unstructured":"Arango-Rodr\u00edguez ML, Mateus LC, Sossa CL, Becerra-Bayona SM, Solarte-David VA, Ochoa Vera ME, et al. A novel therapeutic management for diabetes patients with chronic limb-threatening ischemia: comparison of autologous bone marrow mononuclear cells versus allogenic wharton jelly-derived mesenchymal stem cells. Stem Cell Res Ther. 2023;14(1):221.","journal-title":"Stem Cell Res Ther"},{"issue":"1","key":"1746_CR143","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-025-04148-1","volume":"16","author":"M-Q Yuan","year":"2025","unstructured":"Yuan M-Q, Song L, Wang Z-R, Zhang Z-Y, Shi M, He J, et al. Long-term outcomes of mesenchymal stem cell therapy in severe COVID-19 patients: 3-year follow-up of a randomized, double-blind, placebo-controlled trial. Stem Cell Res Ther. 2025;16(1):94.","journal-title":"Stem Cell Res Ther"},{"issue":"3","key":"1746_CR144","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1164\/rccm.202201-0157OC","volume":"207","author":"ME Bowdish","year":"2023","unstructured":"Bowdish ME, Barkauskas CE, Overbey JR, Gottlieb RL, Osman K, Duggal A, et al. A randomized trial of mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome from COVID-19. Am J Respir Crit Care Med. 2023;207(3):261\u201370.","journal-title":"Am J Respir Crit Care Med"},{"issue":"18","key":"1746_CR145","doi-asserted-by":"publisher","first-page":"e169424","DOI":"10.1172\/jci.insight.169424","volume":"8","author":"M Vivarelli","year":"2023","unstructured":"Vivarelli M, Colucci M, Algeri M, Zotta F, Emma F, L\u2019Erario I, et al. A phase I study of autologous mesenchymal stromal cells for severe steroid-dependent nephrotic syndrome. JCI Insight. 2023;8(18):e169424. https:\/\/doi.org\/10.1172\/jci.insight.169424","journal-title":"JCI Insight"},{"issue":"11","key":"1746_CR146","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1136\/ard-2024-225771","volume":"83","author":"Y-M Pers","year":"2024","unstructured":"Pers Y-M, Soler-Rich R, Vadal\u00e0 G, Ferreira R, Duflos C, Picot M-C, et al. Allogenic bone marrow-derived mesenchymal stromal cell-based therapy for patients with chronic low back pain: a prospective, multicentre, randomised placebo controlled trial (RESPINE study). Ann Rheum Dis. 2024;83(11):1572\u201383.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"1746_CR147","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1158\/1078-0432.CCR-24-2663","volume":"31","author":"A-L Fenger Carlander","year":"2025","unstructured":"Fenger Carlander A-L, Jakobsen KK, Todsen T, Paaske N, \u00d8stergaard Madsen AK, Bendtsen SK, et al. Long-term effectiveness and safety of mesenchymal stromal cell therapy for radiation-induced hyposalivation in head and neck cancer survivors: a randomized phase II trial. Clin Cancer Res. 2025;31(5):824\u201331.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"1746_CR148","doi-asserted-by":"publisher","first-page":"843","DOI":"10.3390\/pharmaceutics13060843","volume":"13","author":"N Attia","year":"2021","unstructured":"Attia N, Mashal M, Puras G, Pedraz JL. Mesenchymal stem cells as a gene delivery tool: promise, problems, and prospects. Pharmaceutics. 2021;13(6):843. https:\/\/doi.org\/10.3390\/pharmaceutics13060843","journal-title":"Pharmaceutics"},{"key":"1746_CR149","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.217081","volume":"597","author":"L Qian","year":"2024","unstructured":"Qian L, Zhang Z, Zhang R, Zheng X, Xiao B, Zhang X, et al. Activated STING-containing R-EVs from iPSC-derived MSCs promote antitumor immunity. Cancer Lett. 2024;597:217081.","journal-title":"Cancer Lett"},{"issue":"30","key":"1746_CR150","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aba6884","volume":"6","author":"O Levy","year":"2020","unstructured":"Levy O, Kuai R, Siren EMJ, Bhere D, Milton Y, Nissar N, et al. Shattering barriers toward clinically meaningful MSC therapies. Sci Adv. 2020;6(30):eaba6884.","journal-title":"Sci Adv"},{"issue":"8","key":"1746_CR151","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1158\/1078-0432.CCR-22-1491","volume":"29","author":"JD Clubb","year":"2023","unstructured":"Clubb JD, Gao TA, Chen YY. Synthetic biology in the engineering of CAR-T and CAR-NK cell therapies: facts and hopes. Clin Cancer Res. 2023;29(8):1390\u2013402.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1746_CR152","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s40364-021-00270-3","volume":"9","author":"K Li","year":"2021","unstructured":"Li K, Chen C, Gao R, Yu X, Huang Y, Chen Z, et al. Inhibition of BCL11B induces downregulation of PTK7 and results in growth retardation and apoptosis in T-cell acute lymphoblastic leukemia. Biomark Res. 2021;9(1):17.","journal-title":"Biomark Res"},{"key":"1746_CR153","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1371345","volume":"15","author":"J Philippova","year":"2024","unstructured":"Philippova J, Shevchenko J, Sennikov S. GD2-targeting therapy: a comparative analysis of approaches and promising directions. Front Immunol. 2024;15:1371345.","journal-title":"Front Immunol"},{"issue":"9","key":"1746_CR154","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.73","volume":"5","author":"R Aliperta","year":"2015","unstructured":"Aliperta R, Cartellieri M, Feldmann A, Arndt C, Koristka S, Michalk I, et al. Bispecific antibody releasing-mesenchymal stromal cell machinery for retargeting T cells towards acute myeloid leukemia blasts. Blood Cancer J. 2015;5(9):e348.","journal-title":"Blood Cancer J"},{"issue":"5","key":"1746_CR155","doi-asserted-by":"publisher","first-page":"112343","DOI":"10.1016\/j.isci.2025.112343","volume":"28","author":"S Tang","year":"2025","unstructured":"Tang S, Zhang Y, Wang P, Tang Q, Liu Y, Lu F, et al. NKG2D-CAR-targeted iPSC-derived MSCs efficiently target solid tumors expressing NKG2D ligand. iScience. 2025;28(5):112343.","journal-title":"iScience"},{"key":"1746_CR156","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1385571","volume":"15","author":"Z Niu","year":"2024","unstructured":"Niu Z, Wu J, Zhao Q, Zhang J, Zhang P, Yang Y. CAR-based immunotherapy for breast cancer: peculiarities, ongoing investigations, and future strategies. Front Immunol. 2024;15:1385571.","journal-title":"Front Immunol"},{"issue":"6","key":"1746_CR157","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/s41408-021-00508-1","volume":"11","author":"W Nawaz","year":"2021","unstructured":"Nawaz W, Huang B, Xu S, Li Y, Zhu L, Yiqiao H, et al. AAV-mediated in vivo CAR gene therapy for targeting human T-cell leukemia. Blood Cancer J. 2021;11(6):119.","journal-title":"Blood Cancer J"},{"issue":"7","key":"1746_CR158","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.3390\/v13071288","volume":"13","author":"W Dong","year":"2021","unstructured":"Dong W, Kantor B. Lentiviral vectors for delivery of gene-editing systems based on CRISPR\/Cas: current state and perspectives. Viruses. 2021;13(7):1288. https:\/\/doi.org\/10.3390\/v13071288","journal-title":"Viruses"},{"issue":"2","key":"1746_CR159","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/s41551-023-01058-6","volume":"8","author":"L Ye","year":"2024","unstructured":"Ye L, Lam SZ, Yang L, Suzuki K, Zou Y, Lin Q, et al. AAV-mediated delivery of a sleeping beauty transposon and an mRNA-encoded transposase for the engineering of therapeutic immune cells. Nat Biomed Eng. 2024;8(2):132\u201348.","journal-title":"Nat Biomed Eng"},{"issue":"12","key":"1746_CR160","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1038\/s41375-024-02444-y","volume":"38","author":"T Lei","year":"2024","unstructured":"Lei T, Wang Y, Zhang Y, Yang Y, Cao J, Huang J, et al. Leveraging CRISPR gene editing technology to optimize the efficacy, safety and accessibility of CAR T-cell therapy. Leukemia. 2024;38(12):2517\u201343.","journal-title":"Leukemia"},{"issue":"1","key":"1746_CR161","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-024-00592-6","volume":"14","author":"R Huang","year":"2025","unstructured":"Huang R, Wang X, Yan H, Tan X, Ma Y, Wang M, et al. Safety and efficacy of CD33-targeted CAR-NK cell therapy for relapsed\/refractory AML: preclinical evaluation and phase I trial. Exp Hematol Oncol. 2025;14(1):1.","journal-title":"Exp Hematol Oncol"},{"issue":"17","key":"1746_CR162","doi-asserted-by":"publisher","first-page":"5020","DOI":"10.1158\/1078-0432.CCR-07-0731","volume":"13","author":"RM Dwyer","year":"2007","unstructured":"Dwyer RM, Potter-Beirne SM, Harrington KA, Lowery AJ, Hennessy E, Murphy JM, et al. Monocyte chemotactic protein-1 secreted by primary breast tumors stimulates migration of mesenchymal stem cells. Clin Cancer Res. 2007;13(17):5020\u20137.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"1746_CR163","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1083\/jcb.200608093","volume":"177","author":"SG Ball","year":"2007","unstructured":"Ball SG, Shuttleworth CA, Kielty CM. Vascular endothelial growth factor can signal through platelet-derived growth factor receptors. J Cell Biol. 2007;177(3):489\u2013500.","journal-title":"J Cell Biol"},{"issue":"10","key":"1746_CR164","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1038\/gt.2008.39","volume":"15","author":"E Spaeth","year":"2008","unstructured":"Spaeth E, Klopp A, Dembinski J, Andreeff M, Marini F. Inflammation and tumor microenvironments: defining the migratory itinerary of mesenchymal stem cells. Gene Ther. 2008;15(10):730\u20138.","journal-title":"Gene Ther"},{"issue":"9","key":"1746_CR165","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1182\/blood-2004-02-0526","volume":"104","author":"RF Wynn","year":"2004","unstructured":"Wynn RF, Hart CA, Corradi-Perini C, O\u2019Neill L, Evans CA, Wraith JE, et al. A small proportion of mesenchymal stem cells strongly expresses functionally active CXCR4 receptor capable of promoting migration to bone marrow. Blood. 2004;104(9):2643\u20135.","journal-title":"Blood"},{"issue":"1","key":"1746_CR166","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/sj.leu.2402763","volume":"17","author":"WJC Rombouts","year":"2003","unstructured":"Rombouts WJC, Ploemacher RE. Primary murine MSC show highly efficient homing to the bone marrow but lose homing ability following culture. Leukemia. 2003;17(1):160\u201370.","journal-title":"Leukemia"},{"issue":"3","key":"1746_CR167","doi-asserted-by":"publisher","first-page":"423","DOI":"10.3727\/096368912X653246","volume":"22","author":"C Xinaris","year":"2013","unstructured":"Xinaris C, Morigi M, Benedetti V, Imberti B, Fabricio AS, Squarcina E, et al. A novel strategy to enhance mesenchymal stem cell migration capacity and promote tissue repair in an injury specific fashion. Cell Transplant. 2013;22(3):423\u201336.","journal-title":"Cell Transplant"},{"issue":"3","key":"1746_CR168","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1007\/s12013-013-9632-6","volume":"67","author":"W Chen","year":"2013","unstructured":"Chen W, Li M, Cheng H, Yan Z, Cao J, Pan B, et al. Overexpression of the mesenchymal stem cell Cxcr4 gene in irradiated mice increases the homing capacity of these cells. Cell Biochem Biophys. 2013;67(3):1181\u201391.","journal-title":"Cell Biochem Biophys"},{"issue":"2","key":"1746_CR169","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1093\/gastro\/goy017","volume":"7","author":"X-B Zheng","year":"2019","unstructured":"Zheng X-B, He X-W, Zhang L-J, Qin H-B, Lin X-T, Liu X-H, et al. Bone marrow-derived CXCR4-overexpressing MSCs display increased homing to intestine and ameliorate colitis-associated tumorigenesis in mice. Gastroenterol Rep. 2019;7(2):127\u201338.","journal-title":"Gastroenterol Rep"},{"issue":"2","key":"1746_CR170","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.jcyt.2015.10.011","volume":"18","author":"M Najar","year":"2016","unstructured":"Najar M, Raicevic G, Fayyad-Kazan H, Bron D, Toungouz M, Lagneaux L. Mesenchymal stromal cells and immunomodulation: a gathering of regulatory immune cells. Cytotherapy. 2016;18(2):160\u201371.","journal-title":"Cytotherapy"},{"issue":"4","key":"1746_CR171","doi-asserted-by":"publisher","first-page":"3114","DOI":"10.1002\/jcp.30080","volume":"236","author":"X Ma","year":"2021","unstructured":"Ma X, Chen J, Liu J, Xu B, Liang X, Yang X, et al. IL-8\/CXCR2 mediates tropism of human bone marrow-derived mesenchymal stem cells toward CD133+ \/CD44\u2009+\u2009colon cancer stem cells. J Cell Physiol. 2021;236(4):3114\u201328.","journal-title":"J Cell Physiol"},{"issue":"1","key":"1746_CR172","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-023-00423-0","volume":"12","author":"M Chen","year":"2023","unstructured":"Chen M, Liu X, Peng N, Zhang T, Mou J, He H, et al. Construction of CD19 targeted dual- and enhanced dual-antibodies and their efficiency in the treatment of B cell malignancy. Exp Hematol Oncol. 2023;12(1):64.","journal-title":"Exp Hematol Oncol"},{"issue":"8","key":"1746_CR173","doi-asserted-by":"publisher","first-page":"3464","DOI":"10.1172\/JCI131246","volume":"129","author":"M Hegde","year":"2019","unstructured":"Hegde M, Mukherjee M, Grada Z, Pignata A, Landi D, Navai SA, et al. Tandem CAR t cells targeting HER2 and IL13R\u03b12 mitigate tumor antigen escape. J Clin Invest. 2019;129(8):3464.","journal-title":"J Clin Invest"},{"issue":"7952","key":"1746_CR174","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/s41586-023-05778-2","volume":"615","author":"AM Tousley","year":"2023","unstructured":"Tousley AM, Rotiroti MC, Labanieh L, Rysavy LW, Kim W-J, Lareau C, et al. Co-opting signalling molecules enables logic-gated control of CAR T cells. Nature. 2023;615(7952):507\u201316.","journal-title":"Nature"},{"issue":"47","key":"1746_CR175","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2312374120","volume":"120","author":"NJ Bangayan","year":"2023","unstructured":"Bangayan NJ, Wang L, Burton Sojo G, Noguchi M, Cheng D, Ta L, et al. Dual-inhibitory domain iCARs improve the efficiency of the and-not gate CAR T strategy. Proc Natl Acad Sci U S A. 2023;120(47):e2312374120.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1746_CR176","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.216871","volume":"591","author":"L Wang","year":"2024","unstructured":"Wang L, Zhang L, Dunmall LC, Wang YY, Fan Z, Cheng Z, et al. The dilemmas and possible solutions for CAR-T cell therapy application in solid tumors. Cancer Lett. 2024;591:216871.","journal-title":"Cancer Lett"},{"issue":"2","key":"1746_CR177","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.cell.2016.09.011","volume":"167","author":"KT Roybal","year":"2016","unstructured":"Roybal KT, Williams JZ, Morsut L, Rupp LJ, Kolinko I, Choe JH, et al. Engineering T cells with customized therapeutic response programs using synthetic Notch receptors. Cell. 2016 Oct 6;167(2):419\u2013432.e16. https:\/\/doi.org\/10.1016\/j.cell.2016.09.011","journal-title":"Cell"},{"issue":"11","key":"1746_CR178","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1097\/CM9.0000000000002818","volume":"137","author":"X Li","year":"2024","unstructured":"Li X, Li W, Xu L, Song Y. Chimeric antigen receptor-immune cells against solid tumors: structures, mechanisms, recent advances, and future developments. Chin Med J (Engl). 2024;137(11):1285\u2013302.","journal-title":"Chin Med J (Engl)"},{"issue":"1","key":"1746_CR179","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-022-03163-w","volume":"13","author":"A Keshavarz","year":"2022","unstructured":"Keshavarz A, Salehi A, Khosravi S, Shariati Y, Nasrabadi N, Kahrizi MS, et al. Recent findings on chimeric antigen receptor (CAR)-engineered immune cell therapy in solid tumors and hematological malignancies. Stem Cell Res Ther. 2022;13(1):482.","journal-title":"Stem Cell Res Ther"},{"issue":"1","key":"1746_CR180","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.ymthe.2016.10.011","volume":"25","author":"X Han","year":"2017","unstructured":"Han X, Bryson PD, Zhao Y, Cinay GE, Li S, Guo Y, et al. Masked chimeric antigen receptor for tumor-specific activation. Mol Ther. 2017;25(1):274\u201384.","journal-title":"Mol Ther"},{"issue":"12","key":"1746_CR181","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.1038\/s41375-024-02409-1","volume":"38","author":"L Volta","year":"2024","unstructured":"Volta L, Myburgh R, Pellegrino C, Koch C, Maurer M, Manfredi F, et al. Efficient combinatorial adaptor-mediated targeting of acute myeloid leukemia with CAR T-cells. Leukemia. 2024;38(12):2598\u2013613.","journal-title":"Leukemia"},{"issue":"7999","key":"1746_CR182","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/s41586-024-07018-7","volume":"626","author":"J Garcia","year":"2024","unstructured":"Garcia J, Daniels J, Lee Y, Zhu I, Cheng K, Liu Q, et al. Naturally occurring T cell mutations enhance engineered T cell therapies. Nature. 2024;626(7999):626\u201334.","journal-title":"Nature"},{"issue":"1","key":"1746_CR183","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s13045-018-0680-7","volume":"11","author":"P Lai","year":"2018","unstructured":"Lai P, Chen X, Guo L, Wang Y, Liu X, Liu Y, et al. A potent immunomodulatory role of exosomes derived from mesenchymal stromal cells in preventing cGVHD. J Hematol Oncol. 2018;11(1):135.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"1746_CR184","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-021-00220-7","volume":"10","author":"T Lyu","year":"2021","unstructured":"Lyu T, Wang Y, Li D, Yang H, Qin B, Zhang W, et al. Exosomes from BM-MSCs promote acute myeloid leukemia cell proliferation, invasion and chemoresistance via upregulation of S100A4. Exp Hematol Oncol. 2021;10(1):24.","journal-title":"Exp Hematol Oncol"},{"key":"1746_CR185","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-019-0159-x","volume":"7","author":"K Yin","year":"2019","unstructured":"Yin K, Wang S, Zhao RC. Exosomes from mesenchymal stem\/stromal cells: a new therapeutic paradigm. Biomark Res. 2019;7:8.","journal-title":"Biomark Res"},{"issue":"12","key":"1746_CR186","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1093\/stcltm\/szae045","volume":"13","author":"U Sajjad","year":"2024","unstructured":"Sajjad U, Ahmed M, Iqbal MZ, Riaz M, Mustafa M, Biedermann T, et al. Exploring mesenchymal stem cells homing mechanisms and improvement strategies. Stem Cells Transl Med. 2024;13(12):1161\u201377.","journal-title":"Stem Cells Transl Med"},{"issue":"5","key":"1746_CR187","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/s41422-023-00789-0","volume":"33","author":"J Chen","year":"2023","unstructured":"Chen J, Qiu S, Li W, Wang K, Zhang Y, Yang H, et al. Tuning charge density of chimeric antigen receptor optimizes tonic signaling and CAR-T cell fitness. Cell Res. 2023;33(5):341\u201354.","journal-title":"Cell Res"},{"issue":"2","key":"1746_CR188","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.immuni.2020.07.011","volume":"53","author":"W Li","year":"2020","unstructured":"Li W, Qiu S, Chen J, Jiang S, Chen W, Jiang J, et al. Chimeric antigen receptor designed to prevent ubiquitination and downregulation showed durable antitumor efficacy. Immunity. 2020;53(2):456\u2013470.e6. https:\/\/doi.org\/10.1016\/j.immuni.2020.07.011","journal-title":"Immunity"},{"issue":"11","key":"1746_CR189","doi-asserted-by":"publisher","first-page":"e009949","DOI":"10.1136\/jitc-2024-009949","volume":"12","author":"Y Dai","year":"2024","unstructured":"Dai Y, Liu Y, An L, Zhong F, Zhang X, Lou S. Afatinib boosts CAR-T cell antitumor therapeutic efficacy via metabolism and fate reprogramming. J Immunother Cancer. 2024;12(11):e009949. https:\/\/doi.org\/10.1136\/jitc-2024-009949","journal-title":"J Immunother Cancer"},{"issue":"1","key":"1746_CR190","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-024-01648-0","volume":"17","author":"Y Liu","year":"2024","unstructured":"Liu Y, An L, Wang X, Dai Y, Zhang C, Wen Q, et al. Engineering a controllable and reversible switch for CAR-based cellular immunotherapies via a genetic code expansion system. J Hematol Oncol. 2024;17(1):122.","journal-title":"J Hematol Oncol"},{"issue":"7949","key":"1746_CR191","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/s41586-023-05707-3","volume":"614","author":"L Labanieh","year":"2023","unstructured":"Labanieh L, Mackall CL. CAR immune cells: design principles, resistance and the next generation. Nature. 2023;614(7949):635\u201348.","journal-title":"Nature"},{"issue":"8047","key":"1746_CR192","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1038\/s41586-024-08261-8","volume":"637","author":"D Steffin","year":"2024","unstructured":"Steffin D, Ghatwai N, Montalbano A, Rathi P, Courtney AN, Arnett AB, et al. Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers. Nature. 2025;637(8047):940\u2013946. https:\/\/doi.org\/10.1038\/s41586-024-08261-8","journal-title":"Nature"},{"issue":"8010","key":"1746_CR193","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/s41586-024-07300-8","volume":"629","author":"AE Doan","year":"2024","unstructured":"Doan AE, Mueller KP, Chen AY, Rouin GT, Chen Y, Daniel B, et al. FOXO1 is a master regulator of memory programming in CAR T cells. Nature. 2024;629(8010):211\u20138.","journal-title":"Nature"},{"issue":"8010","key":"1746_CR194","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41586-024-07242-1","volume":"629","author":"JD Chan","year":"2024","unstructured":"Chan JD, Scheffler CM, Munoz I, Sek K, Lee JN, Huang Y-K, et al. Foxo1 enhances CAR T cell stemness, metabolic fitness and efficacy. Nature. 2024;629(8010):201\u201310.","journal-title":"Nature"},{"issue":"6","key":"1746_CR195","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1016\/j.ymthe.2024.04.004","volume":"32","author":"T Ahn","year":"2024","unstructured":"Ahn T, Bae E-A, Seo H. Decoding and overcoming T cell exhaustion: epigenetic and transcriptional dynamics in CAR-T cells against solid tumors. Mol Ther. 2024;32(6):1617\u201327.","journal-title":"Mol Ther"},{"issue":"1","key":"1746_CR196","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-024-00667-w","volume":"12","author":"S Sui","year":"2024","unstructured":"Sui S, Zhong M, Zhong S, Peng X, Mao L, Chen C, et al. BRD4 inhibitor reduces exhaustion and blocks terminal differentiation in CAR-T cells by modulating BATF and EGR1. Biomark Res. 2024;12(1):124.","journal-title":"Biomark Res"},{"issue":"39","key":"1746_CR197","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202402168","volume":"11","author":"SS Lee","year":"2024","unstructured":"Lee SS, Al Halawani A, Teo JD, Weiss AS, Yeo GC. The matrix protein tropoelastin prolongs mesenchymal stromal cell vitality and delays senescence during replicative aging. Adv Sci (Weinh). 2024;11(39):e2402168.","journal-title":"Adv Sci (Weinh)"},{"issue":"4","key":"1746_CR198","doi-asserted-by":"publisher","first-page":"427","DOI":"10.5966\/sctm.2015-0109","volume":"5","author":"HJ Jin","year":"2016","unstructured":"Jin HJ, Kwon JH, Kim M, Bae YK, Choi SJ, Oh W, et al. Downregulation of melanoma cell adhesion molecule (MCAM\/CD146) accelerates cellular senescence in human umbilical cord blood-derived mesenchymal stem cells. Stem Cells Transl Med. 2016;5(4):427\u201339.","journal-title":"Stem Cells Transl Med"},{"issue":"1","key":"1746_CR199","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1002\/stem.2211","volume":"34","author":"M Okada","year":"2016","unstructured":"Okada M, Kim HW, Matsu-ura K, Wang Y-G, Xu M, Ashraf M. Abrogation of age-induced microrna-195 rejuvenates the senescent mesenchymal stem cells by reactivating telomerase. Stem Cells. 2016;34(1):148\u201359.","journal-title":"Stem Cells"},{"issue":"3","key":"1746_CR200","doi-asserted-by":"publisher","first-page":"4559","DOI":"10.1096\/fj.201801690R","volume":"33","author":"X Liang","year":"2019","unstructured":"Liang X, Ding Y, Lin F, Zhang Y, Zhou X, Meng Q, et al. Overexpression of ERBB4 rejuvenates aged mesenchymal stem cells and enhances angiogenesis via PI3K\/AKT and MAPK\/ERK pathways. FASEB J. 2019;33(3):4559\u201370.","journal-title":"FASEB J"},{"issue":"4","key":"1746_CR201","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.3000201","volume":"17","author":"L Fu","year":"2019","unstructured":"Fu L, Hu Y, Song M, Liu Z, Zhang W, Yu F-X, et al. Up-regulation of FOXD1 by YAP alleviates senescence and osteoarthritis. PLoS Biol. 2019;17(4):e3000201.","journal-title":"PLoS Biol"},{"issue":"6","key":"1746_CR202","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202002058","volume":"10","author":"JRK Samal","year":"2021","unstructured":"Samal JRK, Rangasami VK, Samanta S, Varghese OP, Oommen OP. Discrepancies on the role of oxygen gradient and culture condition on mesenchymal stem cell fate. Adv Healthc Mater. 2021;10(6):e2002058.","journal-title":"Adv Healthc Mater"},{"issue":"11","key":"1746_CR203","doi-asserted-by":"publisher","first-page":"771","DOI":"10.5966\/sctm.2010-0031","volume":"1","author":"B Gharibi","year":"2012","unstructured":"Gharibi B, Hughes FJ. Effects of medium supplements on proliferation, differentiation potential, and in vitro expansion of mesenchymal stem cells. Stem Cells Transl Med. 2012;1(11):771\u201382.","journal-title":"Stem Cells Transl Med"},{"issue":"4","key":"1746_CR204","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s00109-011-0825-4","volume":"90","author":"H-F Yuan","year":"2012","unstructured":"Yuan H-F, Zhai C, Yan X-L, Zhao D-D, Wang J-X, Zeng Q, et al. SIRT1 is required for long-term growth of human mesenchymal stem cells. J Mol Med (Berl). 2012;90(4):389\u2013400.","journal-title":"J Mol Med (Berl)"},{"key":"1746_CR205","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/5841716","volume":"2017","author":"RA Denu","year":"2017","unstructured":"Denu RA. Sirt3 enhances mesenchymal stem cell longevity and differentiation. Oxid Med Cell Longev. 2017;2017:5841716.","journal-title":"Oxid Med Cell Longev"},{"issue":"16","key":"1746_CR206","doi-asserted-by":"publisher","first-page":"2662","DOI":"10.4161\/cc.8.16.9329","volume":"8","author":"B Yang","year":"2009","unstructured":"Yang B, Zwaans BMM, Eckersdorff M, Lombard DB. The sirtuin SIRT6 deacetylates H3 K56Ac in vivo to promote genomic stability. Cell Cycle. 2009;8(16):2662\u20133.","journal-title":"Cell Cycle"},{"issue":"7","key":"1746_CR207","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/s13238-020-00728-4","volume":"11","author":"S Bi","year":"2020","unstructured":"Bi S, Liu Z, Wu Z, Wang Z, Liu X, Wang S, et al. Sirt7 antagonizes human stem cell aging as a heterochromatin stabilizer. Protein Cell. 2020;11(7):483\u2013504.","journal-title":"Protein Cell"},{"issue":"1","key":"1746_CR208","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-023-03352-1","volume":"14","author":"S Calcat-I-Cervera","year":"2023","unstructured":"Calcat-I-Cervera S, Rendra E, Scaccia E, Amadeo F, Hanson V, Wilm B, et al. Harmonised culture procedures minimise but do not eliminate mesenchymal stromal cell donor and tissue variability in a decentralised multicentre manufacturing approach. Stem Cell Res Ther. 2023;14(1):120.","journal-title":"Stem Cell Res Ther"},{"key":"1746_CR209","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2024.1400347","volume":"12","author":"AB \u010cesnik","year":"2024","unstructured":"\u010cesnik AB, \u0160vajger U. The issue of heterogeneity of MSC-based advanced therapy medicinal products-a review. Front Cell Dev Biol. 2024;12:1400347.","journal-title":"Front Cell Dev Biol"},{"issue":"3","key":"1746_CR210","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.3390\/ijms23031439","volume":"23","author":"I Song","year":"2022","unstructured":"Song I, Rim J, Lee J, Jang I, Jung B, Kim K, et al. Therapeutic potential of human fetal mesenchymal stem cells in musculoskeletal disorders: a narrative review. Int J Mol Sci. 2022;23(3):1439. https:\/\/doi.org\/10.3390\/ijms23031439","journal-title":"Int J Mol Sci"},{"issue":"9","key":"1746_CR211","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1182\/bloodadvances.2020001711","volume":"4","author":"J Giri","year":"2020","unstructured":"Giri J, Galipeau J. Mesenchymal stromal cell therapeutic potency is dependent upon viability, route of delivery, and immune match. Blood Adv. 2020;4(9):1987\u201397.","journal-title":"Blood Adv"},{"issue":"1","key":"1746_CR212","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-020-02054-2","volume":"11","author":"S Bahsoun","year":"2020","unstructured":"Bahsoun S, Coopman K, Akam EC. Quantitative assessment of the impact of cryopreservation on human bone marrow-derived mesenchymal stem cells: up to 24\u00a0h post-thaw and beyond. Stem Cell Res Ther. 2020;11(1):540.","journal-title":"Stem Cell Res Ther"},{"issue":"10","key":"1746_CR213","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1039\/D3MD00378G","volume":"14","author":"N Gonzalez-Martinez","year":"2023","unstructured":"Gonzalez-Martinez N, Gibson MI. Post-thaw application of ROCK-inhibitors increases cryopreserved T-cell yield. RSC Med Chem. 2023;14(10):2058\u201367.","journal-title":"RSC Med Chem"},{"issue":"5","key":"1746_CR214","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.tice.2009.01.004","volume":"41","author":"BC Heng","year":"2009","unstructured":"Heng BC. Effect of Rho-associated kinase (ROCK) inhibitor Y-27632 on the post-thaw viability of cryopreserved human bone marrow-derived mesenchymal stem cells. Tissue Cell. 2009;41(5):376\u201380.","journal-title":"Tissue Cell"},{"issue":"2","key":"1746_CR215","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1007\/s40778-022-00212-1","volume":"8","author":"C Cottle","year":"2022","unstructured":"Cottle C, Porter AP, Lipat A, Turner-Lyles C, Nguyen J, Moll G, et al. Impact of cryopreservation and freeze-thawing on therapeutic properties of mesenchymal stromal\/stem cells and other common cellular therapeutics. Curr Stem Cell Rep. 2022;8(2):72\u201392.","journal-title":"Curr Stem Cell Rep"},{"issue":"2","key":"1746_CR216","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.cryobiol.2015.07.003","volume":"71","author":"LA Marquez-Curtis","year":"2015","unstructured":"Marquez-Curtis LA, Janowska-Wieczorek A, McGann LE, Elliott JAW. Mesenchymal stromal cells derived from various tissues: biological, clinical and cryopreservation aspects. Cryobiology. 2015;71(2):181\u201397.","journal-title":"Cryobiology"},{"key":"1746_CR217","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.omtm.2016.12.006","volume":"4","author":"BL Levine","year":"2017","unstructured":"Levine BL, Miskin J, Wonnacott K, Keir C. Global manufacturing of CAR T cell therapy. Mol Ther Methods Clin Dev. 2016;4:92\u2013101. https:\/\/doi.org\/10.1016\/j.omtm.2016.12.006","journal-title":"Mol Ther"},{"issue":"6","key":"1746_CR218","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1016\/j.ymthe.2024.05.023","volume":"32","author":"T Bexte","year":"2024","unstructured":"Bexte T, Ullrich E. Empowering virus-free CAR immune cell therapies. Mol Ther. 2024;32(6):1609\u201311.","journal-title":"Mol Ther"},{"key":"1746_CR219","doi-asserted-by":"publisher","DOI":"10.1016\/j.biotechadv.2024.108350","volume":"72","author":"L Enriquez-Rodriguez","year":"2024","unstructured":"Enriquez-Rodriguez L, Attia N, Gallego I, Mashal M, Maldonado I, Puras G, et al. Expanding the horizon of transient CAR T therapeutics using virus-free technology. Biotechnol Adv. 2024;72:108350.","journal-title":"Biotechnol Adv"},{"issue":"1","key":"1746_CR220","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-024-02746-4","volume":"22","author":"EM McErlean","year":"2024","unstructured":"McErlean EM, McCarthy HO. Non-viral approaches in CAR-NK cell engineering: connecting natural killer cell biology and gene delivery. J Nanobiotechnol. 2024;22(1):552.","journal-title":"J Nanobiotechnol"},{"issue":"7","key":"1746_CR221","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1016\/j.ymthe.2024.05.022","volume":"32","author":"T Bexte","year":"2024","unstructured":"Bexte T, Botezatu L, Miskey C, Gierschek F, Moter A, Wendel P, et al. Engineering of potent CAR NK cells using non-viral sleeping beauty transposition from minimalistic DNA vectors. Mol Ther. 2024;32(7):2357\u201372.","journal-title":"Mol Ther"},{"issue":"6","key":"1746_CR222","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1016\/j.ymthe.2024.04.024","volume":"32","author":"JG Skeate","year":"2024","unstructured":"Skeate JG, Pomeroy EJ, Slipek NJ, Jones BJ, Wick BJ, Chang J-W, et al. Evolution of the clinical-stage hyperactive TcBuster transposase as a platform for robust non-viral production of adoptive cellular therapies. Mol Ther. 2024;32(6):1817\u201334.","journal-title":"Mol Ther"},{"issue":"9","key":"1746_CR223","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1002\/sctm.18-0024","volume":"7","author":"TEG Krueger","year":"2018","unstructured":"Krueger TEG, Thorek DLJ, Denmeade SR, Isaacs JT, Brennen WN. Concise review: mesenchymal stem cell-based drug delivery: the good, the bad, the ugly, and the promise. Stem Cells Transl Med. 2018;7(9):651\u201363.","journal-title":"Stem Cells Transl Med"},{"issue":"7","key":"1746_CR224","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.nucmedbio.2011.03.008","volume":"38","author":"A Gholamrezanezhad","year":"2011","unstructured":"Gholamrezanezhad A, Mirpour S, Bagheri M, Mohamadnejad M, Alimoghaddam K, Abdolahzadeh L, et al. In vivo tracking of 111In-oxine labeled mesenchymal stem cells following infusion in patients with advanced cirrhosis. Nucl Med Biol. 2011;38(7):961\u20137.","journal-title":"Nucl Med Biol"},{"issue":"1","key":"1746_CR225","doi-asserted-by":"publisher","DOI":"10.1186\/s12929-021-00725-7","volume":"28","author":"W-Z Zhuang","year":"2021","unstructured":"Zhuang W-Z, Lin Y-H, Su L-J, Wu M-S, Jeng H-Y, Chang H-C, et al. Mesenchymal stem\/stromal cell-based therapy: mechanism, systemic safety and biodistribution for precision clinical applications. J Biomed Sci. 2021;28(1):28.","journal-title":"J Biomed Sci"},{"issue":"7","key":"1746_CR226","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1089\/ten.tec.2014.0344","volume":"21","author":"A Zanetti","year":"2015","unstructured":"Zanetti A, Grata M, Etling EB, Panday R, Villanueva FS, Toma C. Suspension-expansion of bone marrow results in small mesenchymal stem cells exhibiting increased transpulmonary passage following intravenous administration. Tissue Eng Part C Methods. 2015;21(7):683\u201392.","journal-title":"Tissue Eng Part C Methods"},{"issue":"2","key":"1746_CR227","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s11307-014-0792-6","volume":"17","author":"Z Li","year":"2015","unstructured":"Li Z, Hu X, Mao J, Liu X, Zhang L, Liu J, et al. Optimization of mesenchymal stem cells (MSCs) delivery dose and route in mice with acute liver injury by bioluminescence imaging. Mol Imaging Biol. 2015;17(2):185\u201394.","journal-title":"Mol Imaging Biol"},{"issue":"6","key":"1746_CR228","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1093\/stcltm\/szae020","volume":"13","author":"R Primavera","year":"2024","unstructured":"Primavera R, Regmi S, Yarani R, Levitte S, Wang J, Ganguly A, et al. Precision delivery of human bone marrow-derived mesenchymal stem cells into the pancreas via intra-arterial injection prevents the onset of diabetes. Stem Cells Transl Med. 2024;13(6):559\u201371.","journal-title":"Stem Cells Transl Med"},{"key":"1746_CR229","doi-asserted-by":"publisher","first-page":"345806","DOI":"10.4061\/2010\/345806","volume":"2010","author":"T Wilson","year":"2010","unstructured":"Wilson T, Stark C, Holmbom J, Rosling A, Kuusilehto A, Tirri T, et al. Fate of bone marrow-derived stromal cells after intraperitoneal infusion or implantation into femoral bone defects in the host animal. J Tissue Eng. 2010;2010:345806.","journal-title":"J Tissue Eng"},{"issue":"12","key":"1746_CR230","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1016\/j.jpedsurg.2016.09.041","volume":"51","author":"K Kimura","year":"2016","unstructured":"Kimura K, Kishida T, Wakao J, Tanaka T, Higashi M, Fumino S, et al. Tumor-homing effect of human mesenchymal stem cells in a TH-MYCN mouse model of neuroblastoma. J Pediatr Surg. 2016;51(12):2068\u201373.","journal-title":"J Pediatr Surg"},{"key":"1746_CR231","doi-asserted-by":"publisher","first-page":"5231","DOI":"10.2147\/IJN.S167142","volume":"13","author":"X Wang","year":"2018","unstructured":"Wang X, Gao J, Ouyang X, Wang J, Sun X, Lv Y. Mesenchymal stem cells loaded with paclitaxel-poly(lactic-co-glycolic acid) nanoparticles for glioma-targeting therapy. Int J Nanomed. 2018;13:5231\u201348.","journal-title":"Int J Nanomed"},{"issue":"11","key":"1746_CR232","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.2174\/1389201021666201218130947","volume":"22","author":"P Dali","year":"2021","unstructured":"Dali P, Shende P. Advances in stem cell therapy for brain diseases via the intranasal route. Curr Pharm Biotechnol. 2021;22(11):1466\u201381.","journal-title":"Curr Pharm Biotechnol"},{"issue":"5","key":"1746_CR233","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1038\/gt.2010.170","volume":"18","author":"SH Seo","year":"2011","unstructured":"Seo SH, Kim KS, Park SH, Suh YS, Kim SJ, Jeun SS, et al. The effects of mesenchymal stem cells injected via different routes on modified IL-12-mediated antitumor activity. Gene Ther. 2011;18(5):488\u201395.","journal-title":"Gene Ther"}],"container-title":["Journal of Hematology & Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-025-01746-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-025-01746-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-025-01746-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T11:06:19Z","timestamp":1761908779000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-025-01746-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,27]]},"references-count":233,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1746"],"URL":"https:\/\/doi.org\/10.1186\/s13045-025-01746-7","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,27]]},"assertion":[{"value":"2 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors consent to publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"92"}}